Type 2 Diabetes

A retrospective study challenges preoperative withholding of GLP-1 RAs in diabetes patients undergoing surgery, citing no increased risk of postoperative respiratory complications.

In this episode, hosts break down the latest type 2 diabetes recommendations from the American College of Physicians and offer their perspective on second-line therapies in T2D.

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.

During this Q&A interview, Crandall discussed the takeaways from her portion of an ACP conference presentation on current clinical guidelines in type 2 diabetes.

Meta-analysis of 11 phase 3 trials shows SGLT2 inhibitors reduce cardiovascular event risk by 9% across diverse patient populations.

In this episode, hosts discuss the STEP HFpEF DM trial and the need for fair allocation of incretin-based therapies with ongoing shortages and overwhelming demand.

The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.

Prices of nearly all insulins, SGLT2 inhibitors, and GLP1As could be reduced if robust generic or biosimilar manufacture were enabled.

In this endocrinology month in review for March 2024, we recap the most popular FDA news and pipeline updates as well as recognizing the 2-year anniversary of Diabetes Dialogue.

In this episode, hosts discuss GLP-1 RA use and CGM technology, updates in once-weekly insulins, the concept of continuous ketone monitoring, and practical application of artificial intelligence into care.

In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.

In this episode, hosts discuss top news and updates in automated insulin delivery from ATTD 2024, with a focus on new data from the T1D Exchange and a read-out from the CRISTAL study.

In this episode, Neuen talks about the FLOW trial, the concept of 4 pillars of GDMT for CKD in type 2 diabetes, and how to approach sequencing of these therapies.

Jake Leach, COO of Dexcom, joins the podcast to discuss the historic clearance of the Stelo sensor and other updates in CGM from the company.

On March 08, 2024, the FDA approved semaglutide 2.4 mg (Wegovy) to reduce cardiovascular risk in adults with obesity or overweight and heart disease based on the SELECT trial.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

Seropositivity was associated with greater albuminuria but not peripheral artery disease in a cohort of patients ≥ 50 years of age with type 2 diabetes mellitus.

Initiation of SGLT2 inhibitors reduced the risk of composite anemia outcomes, compared with GLP-1 RA, among patients with type 2 diabetes and CKD.

The FDA has greenlit Dexcom's Stelo Glucose Biosensor System, marking a historic first as the first continuous glucose monitors to be available over-the-counter.

Results of a new analysis underscore the significance of sleep health in mitigating type 2 diabetes risk, revealing that even an optimal diet may not fully offset the negative impact of inadequate sleep.

Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.

A secondary analysis of cross-sectional data found that serum albumin levels negatively correlated with the prevalence of diabetic retinopathy.

In this episode, hosts are joined by SURMOUNT-2 principal investigator Timothy Garvey, MD, to discuss the approval of the tirzepatide for chronic weight management, data from the SURMOUNT-2, -3, and 4 programs, the future of incretin therapies, and more.

Hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.